“In Russia, the procedure for accelerated registration of medicines and obtaining permits for the use of drugs for the treatment of patients with coronavirus is being extended,” the government’s press service said in a statement.
The government noted that such a decision will prevent disruptions in the supply of drugs to pharmacies, hospitals and clinics.
The Federal Medical and Biological Agency expects registration of the drug from COVID-19 "MIR 19" by the end of the year.
The first phase of human clinical trials was completed in March and showed the drug's safety.